文献速递白血病MDS 与骨髓增殖性肿瘤

地西他滨表观遗传预激后给予米托蒽醌、依托泊苷和阿糖胞苷治疗复发/难治性急性髓系白血病或其他高级别髓系肿瘤成人患者的1/2期研究

Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
PubMed 文献 · Leukemia · 2017-05-30

该1/2期研究在52例复发/难治性急性髓系白血病或其他高级别髓系肿瘤成人患者中,评估地西他滨预激5-10天后给予米托蒽醌、依托泊苷和阿糖胞苷(dec/MEC)的安全性与疗效。7天地西他滨被定义为推荐2期剂量(RP2D)。在46例接受≥RP2D治疗的患者中,完全缓解(CR)率为22%,总缓解率为33%,7例(15%)在治疗开始28天内死亡。CR率与匹配的历史对照人群相比更优(观察/预期CR比值=1.77),但与本院两种当代挽救方案(G-CLAC和G-CLAM)的CR率和生存相似。

要点

  • 7天地西他滨预激后dec/MEC的推荐2期剂量(RP2D)为地西他滨7天。
  • ≥RP2D治疗患者CR率22%(10/46),总缓解率33%,7例(15%)28天内死亡。
  • CR率优于匹配历史对照(观察/预期CR比值=1.77),但与G-CLAC和G-CLAM的CR率和生存相似。

核心结论

  • dec/MEC达到预设疗效目标,但未发现其显著优于目前用于复发/难治性AML的其他含阿糖胞苷方案。

研究设计与样本

  • 1/2期研究,纳入52例复发/难治性急性髓系白血病或其他高级别髓系肿瘤成人患者(中位年龄55岁,范围19-72岁)。
  • 地西他滨预激5-10天后给予米托蒽醌、依托泊苷和阿糖胞苷(dec/MEC)。
  • 剂量递增按6-12例患者队列进行;因7天和10天地西他滨的缓解率相似,7天疗程被定义为推荐2期剂量(RP2D)。

主要发现

  • 剂量递增期间所有剂量水平均耐受良好。
  • 在46例接受≥RP2D治疗的患者中,10例(22%)达到完全缓解(CR),其中8例无可测量残留病;另5例达到血小板未完全恢复的CR,总缓解率为33%。
  • 7例(15%)在治疗开始28天内死亡。
  • 感染/中性粒细胞缺乏伴发热、恶心和黏膜炎是最常见的不良事件。
  • CR率与匹配的历史对照人群相比更优(观察/预期CR比值=1.77),但CR率和生存与本院两种当代挽救方案G-CLAC和G-CLAM相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DNA methyltransferase inhibitors sensitize leukemia cells to chemotherapeutics. We therefore conducted a phase 1/2 study of mitoxantrone, etoposide and cytarabine following 'priming' with 5-10 days of decitabine (dec/MEC) in 52 adults (median age 55 (range: 19-72) years) with relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasms. During dose escalation in cohorts of 6-12 patients, all dose levels were well tolerated. As response rates appeared similar with 7 and 10 days of decitabine, a 7-day course was defined as the recommended phase 2 dose (RP2D). Among 46 patients treated at/above the RP2D, 10 (22%) achieved a complete remission (CR), 8 without measurable residual disease; five additional patients achieved CR with incomplete platelet recovery, for an overall response rate of 33%. Seven patients (15%) died within 28 days of treatment initiation. Infection/neutropenic fever, nausea and mucositis were the most common adverse events. While the CR rate compared favorably to a matched historic control population (observed/expected CR ratio=1.77), CR rate and survival were similar to two contemporary salvage regimens used at our institution (G-CLAC (granulocyte colony-stimulating factor (G-CSF); clofarabine; cytarabine) and G-CLAM (G-CSF; cladribine; cytarabine; mitoxantrone)). Thus, while meeting the prespecified efficacy goal, we found no evidence that dec/MEC is substantially better than other cytarabine-based regimens currently used for relapsed/refractory AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Halpern AB, Othus M, Huebner EM, et al. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study. Leukemia. 2017. PMID: 28555084. doi:10.1038/leu.2017.165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。